At the JP Morgan Healthcare Conference
Announcing Mid- to Long-Term Vision for the Next 10 Years
Successful Existing CDO·CMO Businesses
Advancing to the Next Level with New Drug Challenges
[Asia Economy Reporter Cho Hyun-ui] "Over the next 10 years, we will leap forward as a global integrated bio company through expanding production scale, business portfolio, and global bases."
John Lim, President of Samsung Biologics (photo), revealed the mid- to long-term vision on the 13th (local time) at the JP Morgan Healthcare Conference, the world's largest pharmaceutical and bio company investment event. This is his first global stage since becoming CEO in December last year.
President Lim stated, "Following the establishment of a Contract Development Organization (CDO) research and development (R&D) center in San Francisco, USA last year, we plan to sequentially expand to Boston in the US, Europe, and China," adding, "We will solidify our champion position in the existing CDO, Contract Manufacturing Organization (CMO), and biosimilar fields, while also considering new drug businesses."
He is a global bio-pharmaceutical expert with a master's degree in chemical engineering from Stanford University and an MBA from Northwestern University. He has held positions such as head of production, sales, development, and Chief Financial Officer (CFO) at multinational pharmaceutical companies Roche and Genentech. He joined Samsung Biologics in September 2018 and oversaw the operation of Plant 3, the world's largest biopharmaceutical factory.
Upon his inauguration on December 16 last year, President Lim announced his goal to grow Samsung Biologics, currently the world's No. 1 CMO company, into the global No. 1 in all business sectors including CMO, CDO, and Contract Research Organization (CRO) within 10 years.
In his inaugural speech, he said, "We will maintain the No. 1 position in CMO through bold and proactive investments, while elevating the technology and capabilities of CDO and CRO to the global top level," and added, "We will inherit the innovative will and challenging spirit that led Samsung Biologics' growth, strengthen collaboration, and open a new era for Samsung Biologics to leap toward the world’s top tier."
Samsung Biologics plans to focus on the construction of Plant 4 in Songdo, Incheon this year. Scheduled for completion in 2023, Plant 4 is a 'super plant' with a size 1.5 times that of Seoul's Sangam World Cup Stadium. The production scale is expected to reach 256,000 liters, and upon completion, it will once again break the 'world's largest scale' title currently held by Samsung Biologics' Plant 3. Additionally, Samsung Biologics is also promoting the construction of a second bio campus covering 100,000 pyeong in Songdo.
President Lim said, "Recently, the bio industry has seen accelerated global outsourcing trends, pipeline expansion, and an increase in new bio companies, leading to continuous growth in demand for CMO and CDO," and added, "In response to these market demands and diverse customer needs, we plan to secure as many orders as possible before the full operation of Plant 4."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
